Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01584115

Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)

Phase I Clinical Trial of a Therapeutic Vaccine for Malignancies, Comprising the Tumor Antigen NY-ESO-1 in Combination With the Adjuvant MPLA of Bordetella Pertussis. Evaluation of Toxicity and Immunogenicity

Sponsor: Butantan Institute

Conditions Cancer. Lung Cancer. Melanoma. Ovarian Cancer.

Interventions NY-ESO-1 combined with MPLA NY-ESO-1 combined with MPLA vaccine

Updated 5 times since 2017 Last updated: Apr 24, 2012 Started: Jul 31, 2012 Primary completion: Jul 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Cancer. and Lung Cancer., this trial is ongoing. The trial is conducted by Butantan Institute and has accumulated 5 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Butantan Institute
Instituto de Investigação em Imunologia

Data source: Instituto de Investigação em Imunologia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São Paulo, Brazil